Bli medlem
Bli medlem

Du är här

2016-11-22

NeuroVive Pharmaceutical: NeuroVive Pharmaceutical AB Interim Report January - September 2016

New business model generates opportunities

Business operations
Important events July-September 2016

· NeuroVive completed a 10 percent partial acquisition of its
business partner, Isomerase Therapeutics

· NeuroVive received a request to terminate the Company's license
agreement with Arbutus Biopharma

· NeuroVive's strategy for the treatment of mitochondrial disease
was published in Nature Communications

Important events after the end of the period

· The development of CicloMulsion for acute kidney injury was
discontinued and as a consequence the value of the subsidiary
NeuroVive Asia has been written-down by 50 percent and all previously
capitalized expenditure in connection with CicloMulsion has been
recognized as an impaired value in the interim report for the third
quarter

· New business model encompassing out-licensing of projects for
common indications, as well as proprietary development of orphan
indication projects, was communicated

· Positive preclinical results obtained in an experimental model for
non-alcoholic steatohepatitis (NASH), a very serious and common
disease for which no medication is currently available

· In a termination agreement, all rights for NVP018 were returned to
NeuroVive from Arbutus Biopharma. NeuroVive also received material
manufactured by Arbutus valued at USD 1.5 million

Financial information
Third quarter (July - September 2016)

· Net revenues were SEK 0 (0) and other operating income was SEK
16,000 (74,000)

· Loss before tax was SEK 34,290,000 (53,948,000), for further
information see page 6

· Loss per share* was SEK 0.86 (1.75)
· Diluted loss per share** was SEK 0.86 (1.75)
First nine months of the year (January-September 2016)

· Net revenues were SEK 0 (2,502,000) and other operating income was
SEK 90,000 (499,000)

· Loss before tax was SEK 57,265,000 (83,435,000), for further
information see page 6

· Loss per share* was SEK 1.42 (2.78)
· Diluted loss per share** was SEK 1.42 (2.78)
* Profit/loss for the period divided by the average number of shares
before dilution at the end of the period.

**Profit/loss for the period divided by the average number of shares
after dilution at the end of the period.

For more information concerning this report, please contact:
CEO Erik Kinnman, telephone: +46 (0)46-275 62 20

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund
Tel: +46 (0)46 275 62 20 (switchboard)
ir@neurovive.com
www.neurovive.com

-----------------------------------------------------------
http://news.cision.com/neurovive-pharmaceutical/r/neurovive-pharmaceutic...
http://mb.cision.com/Main/6574/2127843/593317.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.